These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The study on the assessment of the new levodopa drug--stalevo (levodopa/carbidopa/entacapone), in treatment of Parkinson's disease in out-patient clinical practice (the results of the open START-M)].
    Author: Boĭko AN, Batysheva TT, Minaeva NG, Babina LA, Vdovichenko TV, Zhuravleva EIu, Shikhkerimov RK, Malykhina EA, Khozova AA, Zaĭtsev KA, Kostenko EV.
    Journal: Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(12):21-4. PubMed ID: 18427455.
    Abstract:
    Despite significant symptomatic effect of levodopa, in most patients the stable 24 hour's effect changed for alterations of movement symptoms (fluctuations, dyskinesia) after 2-3 years of the therapy. These complications may be reduced due to the constant (physiologic) stimulation of post-synaptic dopamine receptors that, to a certain degree, provides the drug stalevo, which contains levodopa and 2 enzyme inhibitors, dopa decarboxylase (carbidopa) and catechol-O-methyltransferase (entacapone). The results of the study demonstrated beneficial effects of stalevo as compared to traditional therapy in patients with "wearing off" and "on-off" phenomena.
    [Abstract] [Full Text] [Related] [New Search]